If you have been reading about retatrutide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
By August 2020, when only a few vaccine candidates were in Phase III trials and were many months away from establishing safety and efficacy, numerous governments pre-ordered more than 2 billion doses at a cost of more than US$5 billion. Pre-orders from the British government for 2021 were for five vaccine doses per person, a number dispiriting to organizations like the WHO and GAVI which are promoting fair and equitable access worldwide, especially for developing countries. In September, CEPI was financially supporting basic and clinical research for nine vaccine candidates, with nine more in evaluation, under financing commitments to manufacture 2 billion doses of three licensed vaccines by the end of 2021. Before 2022, 7–10 billion COVID‑19 vaccine doses may be manufactured worldwide, but the sizable pre-orders by affluent countries – called "vaccine nationalism" – threaten vaccine availability for poorer nations. The RNA vaccines from Moderna and Pfizer-BioNTech are unusually difficult to produce because they rely upon encapsulation of mRNA in lipid nanoparticles, a novel technology which has never been scaled up before for mass production. As of February 2021, this was thought to be the primary bottleneck in the manufacturing of such vaccines. In November 2021, Moderna CEO Stéphane Bancel claimed that the company had a backlog of tens of millions of doses of its vaccine destined for Africa because COVAX or individual governments could not take delivery. He cited delays with dose administration, a shortage of refrigerator space, and delays getting customs documents.
It was around the same time, with the work of Jean-Baptiste Bécœur in particular, that taxidermy became a more serious practice. Louis Dufresne, a taxidermist at the Muséum National d'Histoire Naturelle in France, rediscovered Bécœur's taxidermy process using arsenical soap and made it known through an article in the Nouveau dictionnaire d'histoire naturelle (1803–1804). This technique enabled the museum to build an immense collection of taxidermy birds. In the 19th century, some hunters took their trophies to upholstery shops, where the upholsterers would sew up the animal skins and stuff them with rags and cotton. The term "stuffing" or a "stuffed animal" evolved from this crude form of taxidermy. Professional taxidermists prefer the term "mounting" to "stuffing". More sophisticated cotton-wrapped wire bodies supporting sewn-on cured skins soon followed. Dufresne's methods spread to England in the early 19th century, where updated and non-toxic methods of preservation were developed by some of the leading naturalists of the day, including Rowland Ward and Montague Brown. Ward established one of the earliest taxidermy firms, Rowland Ward Ltd. of Piccadilly. However, the art of taxidermy remained relatively undeveloped, and the specimens remained stiff and unconvincing. Between 1887 and 1894, many naturalist scientists from all over the world went to Costa Rica to research its bird wildlife. At that time, Costa Rica had unique bird species not found in other parts of the world.
=== Psychiatry === Psychiatrists have used thiopental to desensitize patients with phobias and to "facilitate the recall of painful repressed memories." One psychiatrist who worked with thiopental is Jan Bastiaans, who used this procedure to help relieve trauma in surviving victims of the Holocaust. Another notable psychiatrist using thiopental for the first time in the 1960s in psychoanalytic therapy setting - in a somewhat similar way to psycholytic psychotherapy - was the Hungarian-Australian psychiatrist Imre Zádor. He administered thiopental to psychotherapy patients to reduce transferential resistance in cases of anorexia nervosa as well as to resolve unconscious blockages in other cases.
In the United Kingdom, a television advertisement campaign, the Gold Blend couple starring Anthony Head and Sharon Maughan ran in 12 instalments between 1987 and 1993. The first 11 episodes were released as a promotional compilation video called Love Over Gold in 1993. A novelisation of the same name written by Susan Moody (under the pseudonym Susannah James) was released in the same year. The legendary boxer Chris Eubank and soccer star Ian Wright featured separately in television ads in the late 1990s and 2000s. Before the Gold Blend couple made their debut, a series of British adverts for Nescafé starred Gareth Hunt, shown shaking his closed hand and opening it to reveal coffee beans, then smelling the aroma. Greene, who starred in some 26 adverts, commented that the shaking of the beans was crucial to the campaign's success, due to their sexual connotations. By 1986, adverts in this campaign also starred Sarah Greene and Mike Smith. In the 1986 Smash Hits readers poll, Nescafé were simultaneously ranked fifth in the "Best TV Ad" category and first in the "Worst TV Ad" category. In 2003, the company reintroduced the Nescafé brand in Canada and the US, and the product is now known as Nescafé Taster's Choice. It is sold in North American supermarkets in both glass and plastic packaging. While the Nescafé brand was created for soluble coffee, it has subsequently been used as an umbrella brand on a number of instant coffee products, including, in the UK, Gold Blend and Blend 37 freeze-dried coffees.
Sources: en.wikipedia.org
Most soy protein is a relatively heat-stable storage protein. This heat stability enables soy food products requiring high temperature cooking, such as tofu, soy milk and textured vegetable protein (soy flour) to be made. Soy protein is essentially identical to the protein of other legume seeds and pulses. Soy is a complete protein (it contains all 9 essential amino acids). It is a good source of protein for vegetarians and vegans or for people who want to reduce the amount of meat they eat, according to the US Food and Drug Administration:
== Effect on lean mass == Ibutamoren has been shown to sustain activation of the GH–IGF-1 axis, increasing growth hormone secretion by up to 97%, and to increase lean body mass with no change in total fat mass or visceral fat. It is under investigation as a potential treatment for reduced levels of these hormones, such as in children or elderly adults with growth hormone deficiency, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising potential therapy for the treatment of frailty in the elderly. As of June 2017, ibutamoren is in the preclinical stage of development for growth hormone deficiency.
In May 1991, the PDRE (1987-1991) was overthrown by forces consisting of the TPLF and the TPLF-controlled EPRDF with the promise that a recognition of human rights, democracy, the liberalization of the economic sector, and political rehabilitation were soon to follow. The PDRE, the country's newest civilian regime, was actually dominated by leaders of the preceding Derg (1974-1987) a military junta led by Mengistu Haile Mariam that seized power by overthrowing the long-ruling Emperor Haile Selassie I in 1974. The Derg (meaning "committee" or "council") and its leaders were known for dramatically restructuring the country's political and economic institutions, often through the use of suppression and fear, while transforming the central government's role in domestic affairs. Programs such as the extensive villagization schemes carried out in various parts of the country further served as a testament to the regime's commitment to radical reform measures. Once in power, the leaders of the PDRE continued pursuing their aims as former Derg leaders, such as by resuming forced resettlement programs that were deemed nonviable by many and were ultimately met with a considerable amount of international criticism. Scholars have noted that the fall of the PDRE was largely made possible by the loss of both financial and military support from the dwindling Soviet Union, which had previously backed the Derg following their seizure of power in 1974.
Squids do not have the longitudinal muscles that octopus do. Instead, they have a tunic. This tunic is made of layers of collagen and it surrounds the top and the bottom of the mantle. Because they are made of collagen and not muscle, the tunics are rigid bodies that are much stronger than the muscle counterparts. This provides the squids some advantages for jet propulsion swimming. The stiffness means that there is no necessary muscle flexing to keep the mantle the same size. In addition, tunics take up only 1% of the squid mantle's wall thickness, whereas the longitudinal muscle fibers take up to 20% of the mantle wall thickness in octopuses. Also because of the rigidity of the tunic, the radial muscles in squid can contract more forcefully. The mantle is not the only place where squids have collagen. Collagen fibers are located throughout the other muscle fibers in the mantle. These collagen fibers act as elastics and are sometimes named "collagen springs". As the name implies, these fibers act as springs. When the radial and circular muscles in the mantle contract, they reach a point where the contraction is no longer efficient to the forward motion of the creature. In such cases, the excess contraction is stored in the collagen which then efficiently begins or aids in the expansion of the mantle at the end of the jet. In some tests, the collagen has been shown to be able to begin raising mantle pressure up to 50ms before muscle activity is initiated.
== Synthesis == Through the addition of diethylaminoethylthiol to the 2-pyrroline group and oxidation of the sulfate of ostreogrycin A, a structurally more hydrophobic compound is formed. This hydrophobic compound contains a readily ionizable group that is available for salt formation.
Sources: en.wikipedia.org
=== Stratified epithelium === Stratified or compound epithelium differs from simple epithelium in that it is multilayered. It is therefore found where body linings have to withstand mechanical or chemical insult such that layers can be abraded and lost without exposing subepithelial layers. Cells flatten as the layers become more apical, though in their most basal layers, the cells can be squamous, cuboidal, or columnar. Stratified epithelia (of columnar, cuboidal, or squamous type) can have the following specializations:
== In germline cells == In 1957, André and Rouiller first coined the term "nuage". (French for "cloud"). Its amorphous and fibrous structure occurred in drawings as early as in 1933 (Risley). Today, the nuage is accepted to represent a characteristic, electrondense germ plasm organelle encapsulating the cytoplasmic face of the nuclear envelope of the cells destined to the germline fate. The same granular material is also known under various synonyms: dense bodies, mitochondrial clouds, yolk nuclei, Balbiani bodies, perinuclear P granules in Caenorhabditis elegans, germinal granules in Xenopus laevis, chromatoid bodies in mice, and polar granules in Drosophila. Molecularly, the nuage is a tightly interwoven network of differentially localized RNA-binding proteins, which in turn localize specific mRNA species for differential storage, asymmetric segregation (as needed for asymmetric cell division), differential splicing and/or translational control. The germline granules appear to be ancestral and universally conserved in the germlines of all metazoan phyla. Many germline granule components are part of the piRNA pathway and function to repress transposable elements.
The dominions and colonies provided 57 contingents, overwhelmingly of volunteer forces as none had a substantial full-time force; those from Canada alone numbered some 7,400 Altogether, Britain and her empire deployed some half a million soldiers. After the South African War, the Conservative government embarked on a series of reorganisations that had a negative impact on all the auxiliary forces. The Militia was heavily understrength and disorganised, whilst the number of recruits for the Volunteers was falling off and it was becoming apparent that many Volunteer Corps were headed towards financial collapse unless some action was taken. The Territorial Force was created by the Secretary of State for War, Richard Burdon Haldane, following the enactment of the Territorial and Reserve Forces Act 1907 which combined and re-organised the old Volunteer Force with the Yeomanry. As part of the same process, the remaining units of militia were converted to the Special Reserve. Most Volunteer infantry units had unique identities, but lost these in the reorganisation, becoming Territorial battalions of Regular Army infantry regiments. Only one infantry unit, the London Regiment, has maintained a separate identity. The TF was formed on 1 April 1908 and contained fourteen infantry divisions, and fourteen mounted yeomanry brigades. It had an overall strength of approximately 269,000. Haldane designed it to provide a much larger second line for the six divisions of the Expeditionary Force which he was establishing as the centerpiece of the Regular Army.
=== Galactosemia === Galactosemia results from an inability to process galactose, a simple sugar. This deficiency occurs when the gene for galactose-1-phosphate uridylyltransferase (GALT) has any number of mutations, leading to a deficiency in the amount of GALT produced. There are two forms of Galactosemia: classic and Duarte. Duarte galactosemia is generally less severe than classic galactosemia and is caused by a deficiency of galactokinase. Galactosemia renders infants unable to process the sugars in breast milk, which leads to vomiting and anorexia within days of birth. Most symptoms of the disease are caused by a buildup of galactose-1-phosphate in the body. Common symptoms include liver failure, sepsis, failure to grow, and mental impairment, among others. Buildup of a second toxic substance, galactitol, occurs in the lenses of the eyes, causing cataracts. Currently, the only available treatment is early diagnosis followed by adherence to a diet devoid of lactose, and prescription of antibiotics for infections that may develop.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.